Fulgent Genetics CSO sells shares for tax withholding

Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock.

Rhea-AI Filing Summary

Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of common stock. On May 27, 2026, he sold 945 shares at a weighted-average price of $17.60 per share to satisfy tax withholding obligations from vested restricted stock units. After this transaction, Gao directly held 992,062 shares of Fulgent Genetics common stock, so the sale represents only a small fraction of his overall stake.

Insider Trade Summary

Net Seller: 945 shares

Net Sell 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Sold 945 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock	945	$17.60	$17K

Holdings After Transaction: Common Stock — 992,062 shares (Direct)

Footnotes (2)

1. F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
2. F2. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Key Figures

Shares sold: 945 shares Weighted-average sale price: $17.60 per share Sale price range: $17.39–$17.76 per share +2 more

5 metrics

Shares sold 945 shares Common stock sold on May 27, 2026

Weighted-average sale price $17.60 per share Price for 945 shares sold on May 27, 2026

Sale price range $17.39–$17.76 per share Range of prices across multiple sale transactions

Shares held after transaction 992,062 shares Direct holdings of CSO after May 27, 2026 sale

Net shares sold 945 shares Net change from this Form 4, per transactionSummary

Key Terms

restricted stock units, weighted-average sale price, tax withholding obligations, open-market sale

4 terms

restricted stock units financial

"tax withholding obligations that arose upon the vesting of certain restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted-average sale price financial

"The reported price reflects the weighted-average sale price."

tax withholding obligations financial

"sold by the reporting person to satisfy the tax withholding obligations that arose"

open-market sale financial

"transaction_action: open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fulgent Genetics (FLGT) disclose for Hanlin Gao?

Fulgent Genetics disclosed that Chief Scientific Officer Hanlin Gao sold 945 common shares. The sale occurred on May 27, 2026 at a weighted-average price of $17.60 per share, primarily to cover tax withholding obligations from restricted stock unit vesting.

Why did Fulgent Genetics (FLGT) CSO sell 945 shares of common stock?

The 945 shares were sold to satisfy tax withholding obligations tied to vested restricted stock units. These RSUs were granted to Hanlin Gao on February 26, 2024 and previously reported on a Form 4 filed on February 28, 2024, indicating a compensation-related transaction.

At what price did the Fulgent Genetics (FLGT) CSO share sale occur?

The reported weighted-average sale price was $17.60 per share. The shares were actually sold in multiple transactions at prices ranging from $17.39 to $17.76, with the weighted-average figure used for the Form 4 disclosure and detailed pricing available upon request.

How many Fulgent Genetics (FLGT) shares does the CSO hold after this Form 4 sale?

After selling 945 shares, Chief Scientific Officer Hanlin Gao directly holds 992,062 shares of Fulgent Genetics common stock. This indicates the disclosed sale represents only a small portion of his overall position, leaving his remaining ownership largely unchanged by this tax-related transaction.

Was the Fulgent Genetics (FLGT) CSO’s share sale a routine tax transaction?

Yes. The Form 4 footnote explains the 945 shares were sold solely to satisfy tax withholding obligations from restricted stock unit vesting. Such sales are typically mechanistic, reflecting tax requirements rather than a discretionary decision to reduce long-term equity exposure.

How were the Fulgent Genetics (FLGT) CSO’s sale prices distributed?

The 945 shares were sold in multiple transactions between $17.39 and $17.76 per share. The company reported a weighted-average sale price of $17.60, and Gao undertook to provide full trade details, including share amounts and exact prices, upon request to regulators or shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		S		945(1)	D	$17.6(2)	992,062	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

	/s/ Paul Kim as Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)